Sign In
Buy AMPH
$19.94
-0.440 (-2.16%)
At Close: Jul 31, 2026
Amphastar Announces FDA Approval for Ipratropium Bromide HFA
06:00am, Tuesday, 24'th Feb 2026
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbre
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
06:00am, Friday, 20'th Feb 2026
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2025 ended December
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $31.00 Consensus Target Price from Analysts
01:57am, Friday, 20'th Feb 2026
Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) have been assigned a consensus recommendation of "Hold" from the eight research firms that are currently covering the firm, M
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $31.00 Consensus Price Target from Analysts
01:00am, Monday, 26'th Jan 2026
Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) have received a consensus rating of "Hold" from the eight ratings firms that are covering the company, MarketBeat Ratings rep
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
07:36pm, Wednesday, 14'th Jan 2026
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, In
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
06:00am, Wednesday, 07'th Jan 2026
RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at
Amphastar Director Sells 16,679 Shares for $441,800
09:47am, Tuesday, 23'rd Dec 2025
Floyd Petersen exercised and sold 16,679 shares of Amphastar in November, pocketing more than $441,000. He still retains about $2 million worth of shares.
Amphastar Announces FDA Approval for Teriparatide Injection
06:00am, Monday, 15'th Dec 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbre
Capital Fund Management S.A. Takes $931,000 Position in Amphastar Pharmaceuticals, Inc. $AMPH
04:00am, Saturday, 06'th Dec 2025
Capital Fund Management S.A. acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) in the undefined quarter, according to its most recent filing with the Securities and Exchange Co
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
06:00am, Monday, 24'th Nov 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
06:00am, Wednesday, 12'th Nov 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2025 Earnings Call Transcript
12:16pm, Saturday, 08'th Nov 2025
Amphastar Pharmaceuticals, Inc. ( AMPH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication Willi
Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings
07:31pm, Thursday, 06'th Nov 2025
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street es
Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Top Estimates
06:56pm, Thursday, 06'th Nov 2025
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.96 per share a year ago.
